IN2014KN01715A - - Google Patents
Info
- Publication number
- IN2014KN01715A IN2014KN01715A IN1715KON2014A IN2014KN01715A IN 2014KN01715 A IN2014KN01715 A IN 2014KN01715A IN 1715KON2014 A IN1715KON2014 A IN 1715KON2014A IN 2014KN01715 A IN2014KN01715 A IN 2014KN01715A
- Authority
- IN
- India
- Prior art keywords
- antibody
- amino acid
- acid sequence
- cancer
- fragment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 102100029949 Caprin-1 Human genes 0.000 abstract 1
- 101710072528 Caprin-1 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012035238 | 2012-02-21 | ||
| PCT/JP2013/054403 WO2013125654A1 (ja) | 2012-02-21 | 2013-02-21 | 癌の治療及び／又は予防用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN01715A true IN2014KN01715A (OSRAM) | 2015-10-23 |
Family
ID=49005831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1715KON2014 IN2014KN01715A (OSRAM) | 2012-02-21 | 2013-02-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9573993B2 (OSRAM) |
| EP (1) | EP2818483B1 (OSRAM) |
| JP (1) | JP6187256B2 (OSRAM) |
| KR (1) | KR102005786B1 (OSRAM) |
| CN (1) | CN104114582B (OSRAM) |
| AU (1) | AU2013223161B2 (OSRAM) |
| BR (1) | BR112014021102A2 (OSRAM) |
| CA (1) | CA2864869C (OSRAM) |
| DK (1) | DK2818483T3 (OSRAM) |
| ES (1) | ES2643241T3 (OSRAM) |
| HU (1) | HUE034736T2 (OSRAM) |
| IN (1) | IN2014KN01715A (OSRAM) |
| MX (1) | MX357505B (OSRAM) |
| PL (1) | PL2818483T3 (OSRAM) |
| PT (1) | PT2818483T (OSRAM) |
| RU (1) | RU2631804C2 (OSRAM) |
| WO (1) | WO2013125654A1 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2733492T3 (pl) | 2008-08-05 | 2016-08-31 | Toray Industries | Sposób wykrywania nowotworów |
| AU2009278386B2 (en) | 2008-08-05 | 2015-05-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
| KR101805520B1 (ko) * | 2010-02-04 | 2017-12-07 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
| CN103717238B (zh) * | 2011-08-04 | 2016-10-12 | 东丽株式会社 | 胰癌的治疗和/或预防用药物组合物 |
| AU2013223161B2 (en) | 2012-02-21 | 2017-10-19 | Toray Industries, Inc. | Medicinal composition for treating and/or preventing cancer |
| WO2013147169A1 (ja) * | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 肝臓癌の治療及び／又は予防用医薬組成物 |
| DK2832366T3 (en) | 2012-03-30 | 2018-01-22 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF Gallbladder cancer |
| WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
| RU2646464C2 (ru) | 2012-07-19 | 2018-03-05 | Торэй Индастриз, Инк. | Метод детекции рака |
| CN109369808B (zh) | 2012-08-24 | 2023-11-07 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
| EP3031826B1 (en) | 2013-08-09 | 2018-10-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| US10450385B2 (en) | 2014-08-07 | 2019-10-22 | Memorial Sloan Kettering Cancer Center | Anti-ceramide antibodies |
| CN109069628A (zh) | 2016-01-14 | 2018-12-21 | Bps生物科学有限公司 | 抗pd-1抗体及其用途 |
| MY191649A (en) | 2016-03-04 | 2022-07-05 | Jn Biosciences Llc | Antibodies to tigit |
| KR20190022752A (ko) | 2016-06-27 | 2019-03-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| KR20190075921A (ko) | 2016-10-28 | 2019-07-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CN111936164B (zh) | 2018-03-30 | 2024-09-17 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| KR20220034784A (ko) | 2019-06-13 | 2022-03-18 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 아미노벤즈아제핀 화합물, 면역접합체, 및 이의 용도 |
| BR112022006001A2 (pt) | 2019-09-30 | 2022-07-12 | Bolt Biotherapeutics Inc | Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado |
| AU2020369652A1 (en) | 2019-10-25 | 2022-05-12 | Bolt Biotherapeutics, Inc. | Thienoazepine immunoconjugates, and uses thereof |
| BR112022018171A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
| JPWO2021182570A1 (OSRAM) | 2020-03-12 | 2021-09-16 | ||
| KR20220152318A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| EP4119160A4 (en) | 2020-03-12 | 2024-04-03 | Toray Industries, Inc. | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| JP7715041B2 (ja) * | 2020-03-12 | 2025-07-30 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CA3176626A1 (en) | 2020-05-08 | 2021-11-11 | David Dornan | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| IL298111A (en) | 2020-06-02 | 2023-01-01 | Arcus Biosciences Inc | Antibodies to tigit |
| CN116234586A (zh) | 2020-08-13 | 2023-06-06 | 博尔特生物治疗药物有限公司 | 吡唑并氮呯免疫缀合物及其用途 |
| US20240325529A1 (en) | 2021-06-23 | 2024-10-03 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2022270524A1 (ja) | 2021-06-23 | 2022-12-29 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CA3227706A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| MX2024001104A (es) | 2021-07-27 | 2024-02-23 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| CN117651566A (zh) | 2021-07-27 | 2024-03-05 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CA3234604A1 (en) | 2021-10-29 | 2023-05-04 | Shelley Erin ACKERMAN | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| WO2023177821A2 (en) * | 2022-03-16 | 2023-09-21 | Myeloid Therapeutics, Inc. | Binding domains and methods of use thereof |
| WO2024005123A1 (ja) | 2022-06-30 | 2024-01-04 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CN119768182A (zh) | 2022-08-24 | 2025-04-04 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| KR20250052364A (ko) | 2022-08-24 | 2025-04-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| WO2024043258A1 (ja) | 2022-08-24 | 2024-02-29 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2024048541A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| EP4582101A1 (en) | 2022-08-30 | 2025-07-09 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2024135809A1 (OSRAM) | 2022-12-23 | 2024-06-27 | ||
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2025058000A1 (ja) * | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び／又は診断用医薬組成物 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5994524A (en) | 1994-07-13 | 1999-11-30 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| KR20010042435A (ko) | 1998-04-03 | 2001-05-25 | 나가야마 오사무 | 인간조직인자(티에프)에 대한 인간형화항체 및인간형화항체의 제조방법 |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| HUP0203035A3 (en) | 1998-07-14 | 2007-12-28 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
| GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| HK1045332A1 (zh) | 1999-04-02 | 2002-11-22 | Corixa Corporation | 用於治療和診斷肺癌的化合物及其使用方法 |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| CA2388822A1 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| JP2004526401A (ja) | 2000-03-29 | 2004-09-02 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
| ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| WO2002078524A2 (en) | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| CN100448992C (zh) | 2001-05-11 | 2009-01-07 | 麒麟医药株式会社 | 含人抗体λ轻链基因的人类人工染色体 |
| AU2002311909A1 (en) | 2001-05-11 | 2002-11-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| WO2003007889A2 (en) | 2001-07-17 | 2003-01-30 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| RU2319709C2 (ru) | 2001-07-17 | 2008-03-20 | Рисерч Дивелопмент Фаундейшн | Терапевтические агенты, содержащие проапоптозные белки |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP2388265A1 (en) | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP2311870A1 (en) | 2002-11-26 | 2011-04-20 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| WO2005005601A2 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| CA2553826A1 (en) | 2004-01-26 | 2005-12-08 | Debiovision Inc. | Neoplasm-specific polypeptides and their uses |
| ES2387809T3 (es) | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
| WO2005095457A2 (en) | 2004-03-30 | 2005-10-13 | Glaxo Group Limited | Immunoglobulins |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| KR20170134771A (ko) | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Ｈｅｒ 항체의 고정 용량 투여법 |
| CA2598217A1 (en) | 2005-02-18 | 2006-08-24 | Marsha A. Moses | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| KR101310000B1 (ko) | 2005-03-11 | 2013-09-25 | 싸이퍼젠 바이오시스템즈, 인코포레이티드 | 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘 |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| CA2635616A1 (en) | 2006-01-05 | 2007-07-19 | Carlo M. Croce | Microrna expression abnormalities in pancreatic endocrine and acinar tumors |
| CA2642342A1 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| ES2798266T3 (es) | 2007-10-25 | 2020-12-10 | Toray Industries | Método para la detección del cáncer |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| PL2644194T3 (pl) | 2008-03-18 | 2017-09-29 | Genentech, Inc. | Kombinacje koniugatu przeciwciała anty-HER2-lek i docetakselu |
| AU2009278386B2 (en) * | 2008-08-05 | 2015-05-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
| PL2733492T3 (pl) * | 2008-08-05 | 2016-08-31 | Toray Industries | Sposób wykrywania nowotworów |
| HUE031343T2 (hu) | 2008-08-05 | 2017-07-28 | Toray Industries | Immunitásindukáló ágens |
| DK2467401T3 (en) | 2009-08-19 | 2017-03-20 | Merck Patent Gmbh | ANTIBODIES FOR THE DETECTION OF INTEGRIN COMPLEX IN FFPE MATERIAL |
| PL2480671T3 (pl) | 2009-09-22 | 2015-12-31 | Probiogen Ag | Proces produkcji cząsteczek zawierających specjalne struktury glikanowe |
| BR112012018951C8 (pt) | 2010-02-04 | 2020-06-23 | Toray Industries | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
| CN109925511B (zh) | 2010-02-04 | 2024-03-19 | 东丽株式会社 | 用于癌的治疗和/或预防的药物 |
| MX340014B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| PL2532680T3 (pl) | 2010-02-04 | 2015-10-30 | Toray Industries | Kompozycja medyczna do leczenia raka i/lub zapobiegania |
| WO2011096517A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| KR101805520B1 (ko) | 2010-02-04 | 2017-12-07 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| WO2012005550A2 (ko) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
| SG10201703556YA (en) | 2010-07-26 | 2017-06-29 | Servier Lab | Methods and compositions for liver cancer therapy |
| JP4937389B2 (ja) | 2010-08-11 | 2012-05-23 | 三協技研工業株式会社 | 固液分離方法及び固液分離装置 |
| JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
| AU2012290952B2 (en) | 2011-08-04 | 2016-05-05 | Toray Industries, Inc. | Cancer treatment and/or prevention drug composition |
| RU2624049C2 (ru) | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли |
| EP2740794B1 (en) | 2011-08-04 | 2018-04-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| AU2012290957B2 (en) | 2011-08-04 | 2017-04-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| CN103717238B (zh) | 2011-08-04 | 2016-10-12 | 东丽株式会社 | 胰癌的治疗和/或预防用药物组合物 |
| CN104169303B (zh) | 2012-02-21 | 2018-05-29 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| HUE045461T2 (hu) | 2012-02-21 | 2019-12-30 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| DK2818481T3 (da) | 2012-02-21 | 2019-10-14 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
| AU2013223161B2 (en) | 2012-02-21 | 2017-10-19 | Toray Industries, Inc. | Medicinal composition for treating and/or preventing cancer |
| DK2832366T3 (en) * | 2012-03-30 | 2018-01-22 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF Gallbladder cancer |
| WO2013147169A1 (ja) * | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 肝臓癌の治療及び／又は予防用医薬組成物 |
| US9192530B2 (en) | 2013-07-29 | 2015-11-24 | Nacco Materials Handling Group, Inc. | Moveable seat |
-
2013
- 2013-02-21 AU AU2013223161A patent/AU2013223161B2/en active Active
- 2013-02-21 CN CN201380009168.2A patent/CN104114582B/zh active Active
- 2013-02-21 MX MX2014009746A patent/MX357505B/es active IP Right Grant
- 2013-02-21 WO PCT/JP2013/054403 patent/WO2013125654A1/ja not_active Ceased
- 2013-02-21 ES ES13752353.6T patent/ES2643241T3/es active Active
- 2013-02-21 BR BR112014021102A patent/BR112014021102A2/pt not_active Application Discontinuation
- 2013-02-21 US US14/379,872 patent/US9573993B2/en active Active
- 2013-02-21 DK DK13752353.6T patent/DK2818483T3/en active
- 2013-02-21 KR KR1020147020826A patent/KR102005786B1/ko active Active
- 2013-02-21 HU HUE13752353A patent/HUE034736T2/en unknown
- 2013-02-21 IN IN1715KON2014 patent/IN2014KN01715A/en unknown
- 2013-02-21 JP JP2013512277A patent/JP6187256B2/ja active Active
- 2013-02-21 RU RU2014138041A patent/RU2631804C2/ru active
- 2013-02-21 PL PL13752353T patent/PL2818483T3/pl unknown
- 2013-02-21 EP EP13752353.6A patent/EP2818483B1/en active Active
- 2013-02-21 PT PT137523536T patent/PT2818483T/pt unknown
- 2013-02-21 CA CA2864869A patent/CA2864869C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104114582A (zh) | 2014-10-22 |
| RU2631804C2 (ru) | 2017-09-26 |
| PL2818483T3 (pl) | 2018-01-31 |
| US9573993B2 (en) | 2017-02-21 |
| WO2013125654A1 (ja) | 2013-08-29 |
| PT2818483T (pt) | 2017-10-09 |
| DK2818483T3 (en) | 2017-10-23 |
| EP2818483A1 (en) | 2014-12-31 |
| US20150050283A1 (en) | 2015-02-19 |
| AU2013223161B2 (en) | 2017-10-19 |
| CA2864869C (en) | 2021-10-19 |
| JPWO2013125654A1 (ja) | 2015-07-30 |
| EP2818483B1 (en) | 2017-08-02 |
| JP6187256B2 (ja) | 2017-08-30 |
| CA2864869A1 (en) | 2013-08-29 |
| MX2014009746A (es) | 2014-11-14 |
| MX357505B (es) | 2018-07-12 |
| RU2014138041A (ru) | 2016-04-10 |
| BR112014021102A2 (pt) | 2021-12-28 |
| KR102005786B1 (ko) | 2019-07-31 |
| HUE034736T2 (en) | 2018-02-28 |
| KR20140130669A (ko) | 2014-11-11 |
| AU2013223161A1 (en) | 2014-09-11 |
| EP2818483A4 (en) | 2015-09-02 |
| CN104114582B (zh) | 2018-12-21 |
| ES2643241T3 (es) | 2017-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN01715A (OSRAM) | ||
| MX2014001375A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| IN2014KN01713A (OSRAM) | ||
| IN2014KN01714A (OSRAM) | ||
| IN2014KN01716A (OSRAM) | ||
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| MX348578B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| MX351414B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| BR112012019098A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo | |
| MX2014001374A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| EA201490809A1 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| MX2014001370A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| IN2014CN04498A (OSRAM) | ||
| NZ628449A (en) | Neisseria meningitidis compositions and methods thereof | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| IN2014DN07875A (OSRAM) | ||
| MX380750B (es) | Composición farmacéutica para tratar y/o prevenir el cáncer. | |
| CA3084461C (en) | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY THAT BINDS SPECIFICALLY TO THE N-TERMINAL END OF LYSYL TRANSFER RIBONUCLE ACID (NTRNA) SYNTHETASE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A DISEASE RELATED TO IMMUNE CELL MIGRATION | |
| MX2018011133A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| GB201019467D0 (en) | Therapeutic agent | |
| MX2018011109A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |